| The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study |
47 |
| The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2015: a summary |
45 |
| The European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Registry Annual Report 2016: a summary |
34 |
| Renal toxicities associated with pembrolizumab |
25 |
| Risk factors associated with post-kidney transplant malignancies: an article from the Cancer-Kidney International Network |
23 |
| Frailty and chronic kidney disease: current evidence and continuing uncertainties |
19 |
| Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan? |
17 |
| A comparative analysis of survival of patients on dialysis and after kidney transplantation |
17 |
| Cost of hemodialysis in a public sector tertiary hospital of India |
16 |
| Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease |
15 |
| Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis |
15 |
| Evaluation of the efficacy of a medium cut-off dialyser and comparison with other high-flux dialysers in conventional haemodialysis and online haemodiafiltration |
15 |
| What do epidemiological studies tell us about chronic kidney disease of undetermined cause in Meso-America? A systematic review and meta-analysis |
13 |
| Air pollution and kidney disease: review of current evidence |
13 |
| Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension |
12 |
| Developmental pathology of congenital kidney and urinary tract anomalies |
12 |
| Clinical and diagnostic features of Bartter and Gitelman syndromes |
11 |
| Capillary rarefaction from the kidney point of view |
11 |
| Causes and predictors of mortality in biopsy-proven lupus nephritis: the Sarawak experience |
10 |
| Anticoagulant-related nephropathy: systematic review and meta-analysis |
10 |
| Obesity and chronic kidney disease progression-the role of a new adipocytokine: C1q/tumour necrosis factor-related protein-1 |
10 |
| Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German Chronic Kidney Disease study |
9 |
| Management of autosomal-dominant polycystic kidney disease-state-of-the-art |
9 |
| Clinical and pathological phenotype of genetic causes of focal segmental glomerulosclerosis in adults |
9 |
| Comparison of native and transplant kidney biopsies: diagnostic yield and complications |
9 |
| Adherence to medication in patients with chronic kidney disease: a systematic review of qualitative research |
8 |
| Sodium-glucose cotransporter inhibitors: beyond glycaemic control |
8 |
| Emerging targeted strategies for the treatment of autosomal dominant polycystic kidney disease |
8 |
| Porphyria and kidney diseases |
8 |
| The metabolomic quest for a biomarker in chronic kidney disease |
8 |
| Posaconazole-induced hypertension and hypokalemia due to inhibition of the 11 beta-hydroxylase enzyme |
8 |
| Interstitial inflammation and interstitial fibrosis and tubular atrophy predict renal survival in lupus nephritis |
8 |
| Use of machine-learning algorithms to determine features of systolic blood pressure variability that predict poor outcomes in hypertensive patients |
7 |
| Clinical and pathological characteristics of non-diabetic renal disease in type 2 diabetes patients |
7 |
| International Society of Nephrology's 0by25 initiative (zero preventable deaths from acute kidney injury by 2025): focus on diagnosis of acute kidney injury in low-income countries |
7 |
| Antiphospholipase 2 receptor antibody levels to predict complete spontaneous remission in primary membranous nephropathy |
7 |
| Effect of sodium-glucose cotransporter 2 inhibitor on proximal tubular function and injury in patients with type 2 diabetes: a randomized controlled trial |
6 |
| Atypical hemolytic uremic syndrome: a syndrome in need of clarity |
6 |
| Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes |
6 |
| Chronic kidney disease, kidney transplantation and oxidative stress: a new look to successful kidney transplantation |
6 |
| Risk of percutaneous renal biopsy of native kidneys in the evaluation of acute kidney injury |
6 |
| Variable phenotype in HNF1B mutations: extrarenal manifestations distinguish affected individuals from the population with congenital anomalies of the kidney and urinary tract |
6 |
| Patterns of progression of chronic kidney disease at later stages |
6 |
| Trends of renal diseases in Germany: review of a regional renal biopsy database from 1990 to 2013 |
5 |
| Higher albumin:creatinine ratio and lower estimated glomerular filtration rate are potential risk factors for decline of physical performance in the elderly: the Cardiovascular Health Study |
5 |
| Continuous B-cell depletion in frequently relapsing, steroid-dependent and steroid-resistant nephrotic syndrome |
5 |
| Quality of life with conservative care compared with assisted peritoneal dialysis and haemodialysis |
5 |
| The role of endothelial glycocalyx in health and disease |
5 |
| Short-term effects of sevelamer-carbonate on fibroblast growth factor 23 and pulse wave velocity in patients with normophosphataemic chronic kidney disease Stage 3 |
5 |
| Clinical profile and outcome of pigment-induced nephropathy |
5 |
